Not for nothing, but after 30 years of trying to treat my treatment resistant depression, I'm a little over a month into Spravato (esketamine) treatment and it seems to be the only thing that's made a difference without intolerable side effects. In fact, I don't remember a time in my life ever when I've felt this way. The heaviness has lifted, not to be replaced by temporary mania or numbness, but a sort of objective clearness. I still have meltdowns and lapses, but they are growing fewer and I can better see them coming. I no longer feel trapped by them or inside of them. I feel more like I walk beside them. I hold their hand and try to navigate the world together. When I can. When I can. Sometimes they rush ahead. But my relationship with my depression is changing. We are equals now. I am learning to converse with it instead of letting it dictate the terms.
@PsychedelicInstitute https://mastodon.social/@PsychedelicInstitute/116216070749936835
#MentalHealth #TreatmentResistentDepression #TRD #Spravato #Esketamine
Sponsorship of drug and device studies by the manufacturing company leads to more favorable efficacy results and conclusions than sponsorship by other sources. Our analyses suggest the existence of an industry bias that cannot be explained by standard 'Risk of bias' assessments.
Speaker: Samuel Wilkinson, MD Associate Professor of Psychiatry Yale School of Medicine Activity Directors: Robert Ostroff, MD Sina Nikayin, MD Objectives: 1. To learn the fundamental biological differences between ketamine and esketamine 2. To learn the different ways these drugs are regulated in psychiatry 3. To learn the evidence that has compared the two therapies Disclosures: The Yale School of Medicine implemented mechanisms to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity. All CME staff and content reviewers have no relevant financial relationships with commercial interests to disclose. ACCREDITATION and CREDIT DESIGNATION: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Yale School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Our real-world study suggests that esketamine, when used alongside mood stabilizers, is a safe and potentially effective treatment for bipolar depression, demonstrating sustained anti-suicidal benefits without an increased risk of manic switch across both short- and long-term follow-up and across di โฆ
The study findings suggest that esketamine's efficacy as an add-on to antidepressants is modest in treatment-resistant depression (similar to augmentation strategies with atypical antipsychotics) and is absent against suicidality itself. These findings need to be considered in light of esketamine's โฆ
Psychedelic Institute
J. R. DePriest 
:EA DATA. SF:
Sina Nikayin, MD